SLRN: Acelyrin, Inc. Stock

by  •  • Comments Off on SLRN: Acelyrin, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 275.94
Enterprise Value ($M) 202.05
Book Value ($M) 458.29
Book Value / Share 4.55
Price / Book 0.60
NCAV ($M) 448.14
NCAV / Share 4.45
Price / NCAV 0.62

Profitability (mra)
Return on Invested Capital (ROIC) -0.53
Return on Assets (ROA) -0.36
Return on Equity (ROE) -0.39

Liquidity (mrq)
Quick Ratio 18.10
Current Ratio 18.10

Balance Sheet (mrq) ($M)
Current Assets 480.99
Assets 491.14
Liabilities 32.85
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -293.46
Net Income -248.23
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -303.92
Cash from Investing 154.87
Cash from Financing 5.39

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-12 13D/A Tang Capital Management Llc 8.80 20.91
03-07 13G/A T. Rowe Price Investment Management, Inc. 4.60 -63.87
03-06 13D Trium Capital LLP 5.40
02-14 13G/A Citadel Advisors Llc 4.20
02-10 13G/A Integrated Core Strategies (us) Llc 4.70 -8.38
02-10 13D/A Access Industries Management, Llc 5.08
11-12 13G/A Vanguard Group Inc 4.07 0.00
11-08 13G BlackRock, Inc. 6.00 0.00
08-12 13G/A Fmr Llc 3.92 -55.97
2024-03-28 13G AyurMaya Capital Management Company, LP 9.60

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-19 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-03 223,337 833,351 26.80
2025-04-02 892,289 2,586,237 34.50
2025-04-01 127,791 457,558 27.93
2025-03-31 107,095 1,507,266 7.11

(click for more detail)

Similar Companies
SCPH – scPharmaceuticals Inc. SDGR – Schrödinger, Inc.
SLDB – Solid Biosciences Inc. SNDX – Syndax Pharmaceuticals, Inc.
SPRO – Spero Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io